NERV
NASDAQ
$4.37
Minerva Neurosciences Inc (NERV)
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $9.50 (+117.39%)
Market Cap
$189M
Free Cash Flow Yield
-7.85%
Beta (5Y)
0.76
Price Chart
Valuation
Market Cap$189M
Forward P/E11.21
P/S1.87
P/B2.68
Profitability
Gross Profit (TTM)-$9.65M
EBITDA-$137M
Profit Margin17.8%
Operating Margin17.7%
EPS-$9.52
Financial Health
Free Cash Flow Yield-7.85%
Growth & Risk
FCF 5Y CAGR-15.16%
Beta (5Y)0.76
Sharpe Ratio1.01